BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36586421)

  • 41. NTRK gene aberrations in triple-negative breast cancer: detection challenges using IHC, FISH, RT-PCR, and NGS.
    Zito Marino F; Buono S; Montella M; Giannatiempo R; Messina F; Casaretta G; Arpino G; Vita G; Fiorentino F; Insabato L; Sgambato A; Orditura M; Franco R; Accardo M
    J Pathol Clin Res; 2023 Sep; 9(5):367-377. PubMed ID: 37143440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular and Cytogenetic Features of NTRK Fusions Enriched in BRAF and RET Double-Negative Papillary Thyroid Cancer.
    Wu S; Liu Y; Li K; Liang Z; Zeng X
    J Mol Diagn; 2023 Aug; 25(8):569-582. PubMed ID: 37236546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
    Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
    Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
    Rolfo C; Drilon A; Hong D; McCoach C; Dowlati A; Lin JJ; Russo A; Schram AM; Liu SV; Nieva JJ; Nguyen T; Eshaghian S; Morse M; Gettinger S; Mobayed M; Goldberg S; Araujo-Mino E; Vidula N; Bardia A; Subramanian J; Sashital D; Stinchcombe T; Kiedrowski L; Price K; Gandara DR
    Br J Cancer; 2022 Feb; 126(3):514-520. PubMed ID: 34480094
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NTRK gene fusion testing and management in lung cancer.
    Repetto M; Chiara Garassino M; Loong HH; Lopez-Rios F; Mok T; Peters S; Planchard D; Popat S; Rudzinski ER; Drilon A; Zhou C
    Cancer Treat Rev; 2024 Jun; 127():102733. PubMed ID: 38733648
    [TBL] [Abstract][Full Text] [Related]  

  • 47. NTRK fusion-positive colorectal cancer in Japanese population.
    Yonemaru J; Hashimoto T; Takayanagi D; Naka T; Yatabe Y; Kanemitsu Y; Shiraishi K; Sekine S
    Pathol Int; 2021 May; 71(5):355-359. PubMed ID: 33631044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NTRK Gene Fusion Detection in a Pan-Cancer Setting Using the Idylla GeneFusion Assay.
    Sorber L; Van Dorst B; Bellon E; Zwaenepoel K; Lambin S; De Winne K; Lardon F; Pauwels P; Siozopoulou V
    J Mol Diagn; 2022 Jul; 24(7):750-759. PubMed ID: 35550184
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.
    Hernandez S; Conde E; Molero A; Suarez-Gauthier A; Martinez R; Alonso M; Plaza C; Camacho C; Chantada D; Juaneda-Magdalena L; Garcia-Toro E; Saiz-Lopez P; Rojo F; Abad M; Boni V; Del Carmen S; Regojo RM; Sanchez-Frias ME; Teixido C; Paz-Ares L; Lopez-Rios F
    Arch Pathol Lab Med; 2024 Mar; 148(3):318-326. PubMed ID: 37270803
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
    Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
    Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Getting Your Laboratory on Track With Neurotrophic Receptor Tyrosine Kinase.
    Eyerer FIR; Bradshaw G; Vasalos P; Laser JS; Chang CC; Kim AS; Olson DR; Paler RJ; Rosenbaum JN; Walk EE; Willis JE; Yao J; Yohe SL
    Arch Pathol Lab Med; 2023 Aug; 147(8):872-884. PubMed ID: 36508682
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
    Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
    Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
    Leal JL; Peters G; Szaumkessel M; Leong T; Asadi K; Rivalland G; Do H; Senko C; Mitchell PL; Quing CZ; Dobrovic A; Thapa B; John T
    Lung Cancer; 2020 Aug; 146():154-159. PubMed ID: 32540558
    [TBL] [Abstract][Full Text] [Related]  

  • 55. NTRK Fusions Detection in Paediatric Sarcomas to Expand the Morphological Spectrum and Clinical Relevance of Selected Entities.
    Nozzoli F; Lazar AJ; Castiglione F; Campanacci DA; Beltrami G; De Logu F; Caporalini C; Massi D; Roviello G
    Pathol Oncol Res; 2022; 28():1610237. PubMed ID: 35295613
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study.
    Hyrcza MD; Martins-Filho SN; Spatz A; Wang HJ; Purgina BM; Desmeules P; Park PC; Bigras G; Jung S; Cutz JC; Xu Z; Berman DM; Sheffield BS; Cheung CC; Leduc C; Hwang DM; Ionescu D; Klonowski P; Chevarie-Davis M; Chami R; Lo B; Stockley TL; Tsao MS; Torlakovic E
    Mod Pathol; 2024 Jan; 37(1):100384. PubMed ID: 37972928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study.
    Vaughn CP; Costa JL; Feilotter HE; Petraroli R; Bagai V; Rachiglio AM; Marino FZ; Tops B; Kurth HM; Sakai K; Mafficini A; Bastien RRL; Reiman A; Le Corre D; Boag A; Crocker S; Bihl M; Hirschmann A; Scarpa A; Machado JC; Blons H; Sheils O; Bramlett K; Ligtenberg MJL; Cree IA; Normanno N; Nishio K; Laurent-Puig P
    BMC Cancer; 2018 Aug; 18(1):828. PubMed ID: 30115026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NTRK gene fusions are detected in both secretory and non-secretory breast cancers.
    Maund SL; Sokol ES; Ang Houle A; Ross JS; Wilson TR
    Pathol Int; 2022 Mar; 72(3):187-192. PubMed ID: 35102630
    [TBL] [Abstract][Full Text] [Related]  

  • 60. New targets bring hope in squamous cell lung cancer: neurotrophic tyrosine kinase gene fusions.
    Rolfo C; Raez L
    Lab Invest; 2017 Nov; 97(11):1268-1270. PubMed ID: 29085074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.